Davita's biggest risks in the FY2024 10-K
- Medicare and Medicare Advantage reimbursement changes threaten a substantial portion of dialysis revenue.
- Competition, physician and hospital relationships, and patient retention drive growth across kidney care.
- Operational exposure includes information systems, suppliers, pharmaceuticals, joint ventures, debt, and acquisition-related controls.
- Controlling joint ventures represented approximately 30% of U.S. dialysis revenue in 2024.
The risks most specific to Davita
- Risks Related to the Operation of our Business
Changes in the structure of and payment rates under the Medicare ESRD or Medicare Advantage programs or changes in state Medicaid or other non-Medicare government-based programs or payment rates could have a material adverse effect on our business, results of operations, financial condition and cash flows
Medicare ESRD, Medicare Advantage, Medicaid, and other government payment changes could reduce reimbursement for dialysis treatments.
- Risks Related to the Operation of our Business
If we are unable to compete successfully, including, without limitation, implementing our growth strategy and/or retaining patients and developing and maintaining relationships with physicians and hospitals, it could materially adversely affect our business, results of operations, financial condition and cash flows
Intense kidney-care competition could hinder patient retention, acquisitions, growth initiatives, and relationships with physicians and hospitals.
- Risks Related to the Operation of our Business
Changes in clinical practices, payment rates or regulations impacting pharmaceuticals and/or devices could have a material adverse effect on our business, results of operations, financial condition, and cash flows and negatively impact our ability to care for patients
Changes in clinical practices, reimbursement, or regulation for bundled pharmaceuticals and dialysis devices could increase costs or impair patient care.
- Risks Related to the Operation of our Business
These risks could have a material adverse effect on our business, results of operations, financial condition and cash flows and could materially harm our reputation
Failures or regulatory noncompliance involving DaVita’s clinical, billing, collections, or third-party information systems could disrupt operations and harm reputation.
- Risks Related to the Operation of our Business
If our joint ventures were found to violate the law, we could suffer severe consequences that would have a material adverse effect on our business, results of operations, financial condition and cash flows and could materially harm our reputation
Legal violations by joint ventures could create severe consequences; controlled dialysis joint ventures generated about 30% of 2024 U.S. dialysis revenue.
- General Risk Factors
The level of our current and future debt could have an adverse impact on our business, and our ability to generate cash to service our indebtedness and for other intended purposes and our ability to maintain compliance with debt covenants depends on many factors beyond our control
Substantial existing or future debt, including debt financing share repurchases, could constrain cash use and threaten covenant compliance.
- General Risk Factors
If we fail to successfully maintain an effective internal control over financial reporting, the integrity of our financial reporting could be compromised, which could have a material adverse effect on our ability to accurately report our financial results, the market's perception of our business and our stock price
Integrating acquisitions and new business lines is increasing management demands and compliance costs for internal financial controls.
- Risks Related to the Operation of our Business
For additional information about our assessment of our cybersecurity risks, see discussion in Part I Item 1C. "Cybersecurity."
Supplier failures, supply-price increases, inadequate drug reimbursement, or limited access to better technology could impair dialysis services.
Risk factor headings as read
Headings as the filing states them, in filing order.
Risks Related to the Operation of our Business
- 01Changes in federal and state legislation or regulations could have a material adverse effect on our business, results of operations, financial condition and cash flows
- 02Changes in the structure of and payment rates under the Medicare ESRD or Medicare Advantage programs or changes in state Medicaid or other non-Medicare government-based programs or payment rates could have a material adverse effect on our business, results of operations, financial condition and cash flows
- 03For additional information about our assessment of our cybersecurity risks, see discussion in Part I Item 1C. "Cybersecurity."
- 04Changes in clinical practices, payment rates or regulations impacting pharmaceuticals and/or devices could have a material adverse effect on our business, results of operations, financial condition, and cash flows and negatively impact our ability to care for patients
- 05If we are unable to compete successfully, including, without limitation, implementing our growth strategy and/or retaining patients and developing and maintaining relationships with physicians and hospitals, it could materially adversely affect our business, results of operations, financial condition and cash flows
- 06Issues relating to the failure to comply with applicable non-U.S. laws, requirements or restrictions may also impact our domestic business and/or raise scrutiny on our domestic practices
- 07These risks could have a material adverse effect on our business, results of operations, financial condition and cash flows and could materially harm our reputation
- 08If our joint ventures were found to violate the law, we could suffer severe consequences that would have a material adverse effect on our business, results of operations, financial condition and cash flows and could materially harm our reputation
- 09Our goals and disclosures related to ESG matters expose us to numerous risks, including without limitation risks to our reputation and stock price
General Risk Factors
- 10The level of our current and future debt could have an adverse impact on our business, and our ability to generate cash to service our indebtedness and for other intended purposes and our ability to maintain compliance with debt covenants depends on many factors beyond our control
- 11We could be subject to adverse changes in tax laws, regulations and interpretations or challenges to our tax positions
- 12The effects of natural or other disasters, political instability, public health crises or adverse weather events such as hurricanes, earthquakes, fires or flooding could have a material adverse effect on our business, results of operations, financial condition and cash flows
- 13We may be subject to liability claims for damages and other expenses that are not covered by insurance or exceed our existing insurance coverage that could have a material adverse effect on our business, results of operations, financial condition and cash flows and could materially harm our reputation
- 14If we fail to successfully maintain an effective internal control over financial reporting, the integrity of our financial reporting could be compromised, which could have a material adverse effect on our ability to accurately report our financial results, the market's perception of our business and our stock price
- 15Most of our outstanding employee stock-based compensation awards include a provision accelerating the vesting of the awards in the event of a change of control under certain circumstances. These and any other change of control provisions may affect the price an acquirer would be willing to pay for our Company
Other Davita 10-Ks
- FY2025 10-K risk factors25 risks16 new8 dropped5 reworded
DaVita faces rising labor costs, unionization pressures, and heavy reliance on Medicare and commercial insurance reimbursement rates.
Filed Feb 11, 2026
About this page
The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.